Selloff or Market Correction? Either Way, Here's What to Do NextSee Overvalued Stocks

GSK to spend up to $3.3 billion on Affinivax to boost vaccines roster

Published 05/31/2022, 02:11 AM
Updated 05/31/2022, 04:15 AM
© Reuters. FILE PHOTO: Signage for GlaxoSmithKline is seen on it's offices in London, Britain, March 30, 2016. REUTERS/Toby Melville/File Photo
SRRA
-

By Pushkala Aripaka

(Reuters) -GSK on Tuesday agreed to buy U.S. biotech Affinivax for up to $3.3 billion, its second major deal in two months, giving the British pharmaceutical giant access to the company's roster of next-generation vaccines.

GSK, one of the world's major vaccine makers, has been under pressure to shore up its pharmaceutical pipeline ahead of the separation in July of its consumer business, home to brands such as Sensodyne toothpaste and Advil painkillers.

The drugmaker's newer shingles vaccine has been a key growth driver as demand has returned after disruption to immunisations during the pandemic, but GSK needs a new product to bolster the vaccines business, which made 6.78 billion pounds ($8.54 billion) in 2021.

GSK is also facing competition from vaccine candidates from rivals Pfizer (NYSE:PFE) and Moderna (NASDAQ:MRNA) using newer mRNA technology.

GSK will pay Affinivax $2.1 billion upfront and up to $1.2 billion in potential milestones. The acquisition comes after GSK last month indicated an appetite for further deals following its $1.9 billion purchase of Sierra Oncology (NASDAQ:SRRA).

"While this marks a step in the right direction with regard to the group's strategy, we're mindful that owning the treatment and making money from it are two very different things," said Hargreaves Lansdown (LON:HRGV) analyst Laura Hoy.

London-listed GSK on Tuesday also reiterated its outlook for 2022 and its medium-term targets.

Privately-held Affinivax gives GSK its next-generation vaccines under development, the most advanced of which are for pneumococcal diseases, such as pneumonia, meningitis, bloodstream infections and sinusitis.

GSK has its own, older, pneumococcal vaccine called Synflorix, which was approved for European and U.S. use in 2009, and which competes with Pfizer's Prevnar and Merck's Pneumovax.

© Reuters. GSK logo is seen in this illustration taken on January 17, 2022. REUTERS/Dado Ruvic/Illustration

Affinivax's newer vaccine technology is designed to strengthen the breadth of immunity against a pathogen, such that an immune-boosting adjuvant is not necessary.

($1 = 0.7942 pounds)

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.